Literature DB >> 23675779

Type I and type II interferons inhibit both basal and tumor necrosis factor-α-induced CXCL8 secretion in primary cultures of human thyrocytes.

Mario Rotondi1, Francesca Coperchini, Riccardo Sideri, Gloria Groppelli, Luca de Martinis, Laura Villani, Patrizia Pignatti, Flavia Magri, Luca Chiovato.   

Abstract

Interferons (IFNs) and tumor necrosis factor-α (TNF-α) cooperate in activating several inflammation-related genes, which sustain chronic inflammation in autoimmune thyroid disease (AITD). Much is known about the positive signaling of IFNs to activate gene expression in AITD, while the mechanisms by which IFNs negatively regulate genes remain less studied. While IFNs inhibit CXCL8 secretion in several human cell types, their effects on thyroid cells were not evaluated. Our aim was to study the interplay between TNF-α and type I or type II IFNs on CXCL8 secretion by human thyroid cells. CXCL8 was measured in supernatants of primary cultures of thyroid cells basally and after a 24-h incubation with TNF-α. CXCL8 was detected in thyroid cell supernatants in basal conditions (96.2±23.5 pg/mL) being significantly increased (784.7±217.3 pg/mL; P<0.0001 vs. basal) by TNF-α. Twenty-four hour incubation with IFN-γ or IFN-β or IFN-α dose dependently and significantly inhibited both basal and TNF-α-induced CXCL8 secretion. The degree of the inhibitory effect was IFN-γ>IFN-β>IFN-α. This study demonstrates that type I and type II IFNs downregulate both basal and TNF-α-induced CXCL8 secretion by human thyrocytes, IFN-γ being the most powerful inhibitor. Future studies aimed at a better comprehension of the interplay between CXCL8 and thyroid diseases appear worthwhile.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23675779     DOI: 10.1089/jir.2012.0080

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.

Authors:  O Awwad; F Coperchini; P Pignatti; M Denegri; S Massara; L Croce; C A Di Buduo; V Abbonante; A Balduini; L Chiovato; M Rotondi
Journal:  J Endocrinol Invest       Date:  2018-03-15       Impact factor: 4.256

2.  Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-α-induced CXCL8 secretion.

Authors:  Francesca Coperchini; Patrizia Pignatti; Paola Leporati; Andrea Carbone; Laura Croce; Flavia Magri; Luca Chiovato; Mario Rotondi
Journal:  Endocrine       Date:  2015-10-08       Impact factor: 3.633

3.  Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.

Authors:  Mario Rotondi; Francesca Coperchini; Oriana Awwad; Patrizia Pignatti; Christian A Di Buduo; Vittorio Abbonante; Flavia Magri; Alessandra Balduini; Luca Chiovato
Journal:  Mediators Inflamm       Date:  2016-07-31       Impact factor: 4.711

Review 4.  Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?

Authors:  Mario Rotondi; Francesca Coperchini; Francesco Latrofa; Luca Chiovato
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-21       Impact factor: 5.555

5.  The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.

Authors:  Francesca Coperchini; Laura Croce; Marco Denegri; Oriana Awwad; Samuel Tata Ngnitejeu; Marina Muzza; Valentina Capelli; Francesco Latrofa; Luca Persani; Luca Chiovato; Mario Rotondi
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

Review 6.  The multifaceted anti-cancer effects of BRAF-inhibitors.

Authors:  Laura Croce; Francesca Coperchini; Flavia Magri; Luca Chiovato; Mario Rotondi
Journal:  Oncotarget       Date:  2019-11-12

7.  The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes.

Authors:  Francesca Coperchini; Laura Croce; Marco Denegri; Oriana Awwad; Samuel Tata Ngnitejeu; Flavia Magri; Luca Chiovato; Mario Rotondi
Journal:  Oncotarget       Date:  2019-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.